> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Review Period Set for Biogen’s Alprolix
- URL: https://www.fdaweb.com/review-period-set-for-biogens-alprolix/
- Published: 2016-06-08T12:00:00.000Z
- Updated: 2026-09-14T21:08:22.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5135876

*Federal Register* Notice: FDA has determined the regulatory review period for Biogen Idec Hemophilia Inc.’s Alprolix is 2,223 days for extending patents which claim the human biological product. Alprolix is a recombinant DNA derived, coagulation Factor IX concentrate indicated in adults and children with hemophilia B for controlling and preventing bleeding episodes, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes. To view this notice, click [here.](https://www.gpo.gov/fdsys/pkg/FR-2016-06-08/pdf/2016-13526.pdf?ref=fdaweb.com)